CoChat
Sign Up
Cited by 304Growth Hormone and Insulin-like Growth FactorsCytokine Signaling Pathways and InteractionsReceptor Mechanisms and Signaling

The DOI matches its Crossref record; 330 of the 330 references it cites were found in a registry or an index.

The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects

Open access
Dehkhoda, Farhad, Lee, Christine M. M., Medina, Johan, Brooks, Andrew J.·2018·Frontiers in Endocrinology
DOI 10.3389/fendo.2018.00035PMC PMC5816795
Open this paper in CoChat — free accountOpen PDF

Abstract

The growth hormone receptor (GHR), although most well known for regulating growth, has many other important biological functions including regulating metabolism and controlling physiological processes related to the hepatobiliary, cardiovascular, renal, gastrointestinal, and reproductive systems. In addition, growth hormone signaling is an important regulator of aging and plays a significant role in cancer development. Growth hormone activates the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, and recent studies have provided a new understanding of the mechanism of JAK2 activation by growth hormone binding to its receptor. JAK2 activation is required for growth hormone-mediated activation of STAT1, STAT3, and STAT5, and the negative regulation of JAK-STAT signaling comprises an important step in the control of this signaling pathway. The GHR also activates the Src family kinase signaling pathway independent of JAK2. This review covers the molecular mechanisms of GHR activation and signal transduction as well as the physiological consequences of growth hormone signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2018.00035

Cites

330 of 330 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The growth hormone receptor domain organization.
Figure 1 The growth hormone receptor domain organization.CC BY · PubMed Central
Figure 2 Activation of the growth hormone receptor (GHR) by growth hormone. In the inactive homodimeric GHR, (A) the Janus kinase (JAK) 2 kinase domain (KD) is inhibited in trans by interaction with the pseudokinase domain from the JAK2 bound to the opposing receptor within the homodimer. GH binding to the GHR extracellular domain (B) results in conformational changes that cause the transmembrane domains to transition from a parallel interaction to a left-handed crossover interaction. These structural changes cause a separation of the intracellular domains to the Box1 and Box2 motifs and the associated JAK2 molecules. The movement of the associated JAK2s dissociates the inhibitory interaction of the pseudokinase from the KD and brings the two JAK2 KDs in close proximity resulting in trans phosphorylation and activation.
Figure 2 Activation of the growth hormone receptor (GHR) by growth hormone. In the inactive homodimeric GHR, (A) the Janus kinase (JAK) 2 kinase domain (KD) is inhibited in trans by interaction with the pseudokinase domain from the JAK2 bound to the opposing receptor within the homodimer. GH binding to the GHR extracellular domain (B) results in conformational changes that cause the transmembrane domains to transition from a parallel interaction to a left-handed crossover interaction. These structural changes cause a separation of the intracellular domains to the Box1 and Box2 motifs and the associated JAK2 molecules. The movement of the associated JAK2s dissociates the inhibitory interaction of the pseudokinase from the KD and brings the two JAK2 KDs in close proximity resulting in trans phosphorylation and activation.CC BY · PubMed Central
Figure 3 The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway initiated by the activated growth hormone receptor. Activated JAK2 phosphorylates tyrosines on the intracellular domain of the receptor. Inactive-STAT5 dimers bind these phosphorylated tyrosine residues on the receptor, and the STAT5 is subsequently phosphorylated by JAK2 forming different active-STAT5 dimers that are translocated to the nucleus, bind DNA, and act as transcription factors. STAT1 and STAT3 are phosphorylated and activated by JAK2. Active STAT1 and STAT3 form homodimers or heterodimers, are translocated to the nucleus, bind DNA, and act as transcription factors.
Figure 3 The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling pathway initiated by the activated growth hormone receptor. Activated JAK2 phosphorylates tyrosines on the intracellular domain of the receptor. Inactive-STAT5 dimers bind these phosphorylated tyrosine residues on the receptor, and the STAT5 is subsequently phosphorylated by JAK2 forming different active-STAT5 dimers that are translocated to the nucleus, bind DNA, and act as transcription factors. STAT1 and STAT3 are phosphorylated and activated by JAK2. Active STAT1 and STAT3 form homodimers or heterodimers, are translocated to the nucleus, bind DNA, and act as transcription factors.CC BY · PubMed Central
Figure 4 The Src family kinase (SFK) signaling initiated by the activated growth hormone receptor (GHR). SFKs are activated by GH binding to GHR. This signaling pathway activates ERK1/2 that regulates cytosolic targets and gene transcription.
Figure 4 The Src family kinase (SFK) signaling initiated by the activated growth hormone receptor (GHR). SFKs are activated by GH binding to GHR. This signaling pathway activates ERK1/2 that regulates cytosolic targets and gene transcription.CC BY · PubMed Central
Figure 5 The major negative regulation of growth hormone receptor (GHR) signaling. GH-activated GHR results in suppressor of cytokine signaling (SOCS) 2 binding to a phosphorylated tyrosine on the GHR intracellular domain. This blocks signal transducer and activator of transcription (STAT) 5 binding and induces ubiquitination of the GHR leading to targeted degradation of the receptor. SHP1 and SHP2 act to dephosphorylate and inactivate Janus kinase 2 and STATs, while SHP2 is known to also dephosphorylate the receptor.
Figure 5 The major negative regulation of growth hormone receptor (GHR) signaling. GH-activated GHR results in suppressor of cytokine signaling (SOCS) 2 binding to a phosphorylated tyrosine on the GHR intracellular domain. This blocks signal transducer and activator of transcription (STAT) 5 binding and induces ubiquitination of the GHR leading to targeted degradation of the receptor. SHP1 and SHP2 act to dephosphorylate and inactivate Janus kinase 2 and STATs, while SHP2 is known to also dephosphorylate the receptor.CC BY · PubMed Central
Figure 6 Organ-specific roles of the GH/insulin-like growth factor-1 (IGF-1) axis.
Figure 6 Organ-specific roles of the GH/insulin-like growth factor-1 (IGF-1) axis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 330 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Dehkhoda, F., Lee, C. M. M., Medina, J., & Brooks, A. J.
Affiliations
Translational Research Institute (AU)
Corresponding author
Brooks, Andrew J.
ORCID
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2018-02-13
Volume
9
Pages
35-35
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2018.00035
PMC
PMC5816795
OpenAlex
W2790718366
Cited by
304
References
330
Citations by year
2026: 37 · 2025: 41 · 2024: 33 · 2023: 46 · 2022: 46 · 2021: 50 · 2020: 35 · 2019: 13 · 2018: 3
FWCI
3.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RUNE (Research UNE) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Health and Medical Research Council (APP1084797)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
growth hormone receptor, receptor activation, JAK/STAT signaling, JAK2 activation, STAT1, STAT3, STAT5, Src family kinases, signal transduction, growth hormone physiology, aging, cancer, metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review